Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹30.24 Cr |
| Reserved for Market Maker | ₹1.71 Cr |
| Net Issue Size | ₹30.24 Cr |
| Fresh Issue | ₹28.53 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹196.00-208.00 per share |
| NSE Code | AVIENCE |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,200 shares · Multiples of 600 shares
Avience Biomedicals IPO comprises a total issue size of 14,53,800 shares. The net offer to the public is 13,71,600 shares, after excluding 82,200 shares allotted on a firm basis. Of the Net offer 6,83,400 (49.83%) are allocated to QIB, 2,07,000 (15.09%) allocated to NII 4,81,200 (35.08%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 6,83,400 | 49.83% | 47.01% |
| − Anchor Investor Shares Offered | 4,09,800 | 28.19% | |
| − QIB (Ex. Anchor) Shares Offered | 2,73,600 | 18.82% | |
| NII (HNI) Shares Offered | 2,07,000 | 15.09% | 14.24% |
| − bNII > ₹10L | 1,38,000 | 9.49% | |
| − sNII < ₹10L | 69,000 | 4.75% | |
| Retail Shares Offered | 4,81,200 | 35.08% | 33.10% |
| Firm Reservations | |||
| Market Maker Shares Offered | 82,200 | 5.65% | |
| Total Shares Offered | 14,53,800 | 100.00% | 100.00% |
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
As of December 2024, the company had 65 permanent employees and 33 contractual employees
Competitive Strength
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 14.05 |
| 2 | Funding the working capital requirements of the Company | 8.25 |
| 3 | General Corporate Purposes | 3.97 |
| 4 | Public Issue Expenses | 3.97 |
| Total | 30.24 |
| Period Ended | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
| Amount in ₹ Crore | |||
| KPI | Jan 31, 206 | Mar 31, 2025 |
|---|---|---|
| ROE | 22.38% | 50.14% |
| ROCE | 16.99% | 24.84% |
| Debt / Equity | 0.94% | 0.97% |
| RoNW | 22.38% | 49.89% |
| PAT Margin | 15.86% | |
| EBITDA Margin | 24.70% | 25.22% |
| Price to Book Value | 2.94 | 3.68 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 17.94 | 12.56 |
| P/E (x) | 11.59 | 16.56 |
| Promoter Holding | 87.89% | 64.59% |
| Market Cap | ₹114.09 Cr. | |
